已收盤 11-20 16:00:00 美东时间
-0.135
-14.16%
11月21日,Fractyl Health(GUTS)收跌14.16%,报0.82美元,成交额29.04万美元,市值1087.73万美元。 行情数据 • 开盘价...
11-21 08:58
英伟达盘前再跌4%!分析师警告黄仁勋回归可能性几乎为零;英特尔CEO也遭起诉!盘前股价跌超5%;美联储要加息50基点?华尔街聚焦今夜凌晨1:00沃什讲话>>
11-16 21:32
今日重点评级关注:Canaccord Genuity:维持Fractyl Health"买入"评级,目标价从39美元升至40美元;HC Wainwright & Co.:维持Fractyl Health"买入"评级,目标价从8美元升至24美元
11-16 20:14
11月14日,Fractyl Health(GUTS)收涨11.27%,报0.9美元,成交额38.35万美元,市值1198.57万美元。 行情数据 • 开盘价...
11-14 08:55
HC Wainwright & Co. analyst Joseph Pantginis maintains Fractyl Health (NASDAQ:GUTS) with a Buy and raises the price target from $8 to $24.
11-13 20:27
11月10日,Fractyl Health(GUTS)收跌3.52%,报0.9美元,成交额24.77万美元,市值1190.02万美元。 行情数据 • 开盘价:...
11-10 09:04
Fractyl Health, Inc. will report Q3 2026 financial results and provide updates on November 12, 2026, at 4:30 p.m. ET. A live webcast will be available on the company's website, and shareholders can submit questions via Say Technologies' platform until November 11, 2026. Fractyl focuses on innovative treatments for obesity and type 2 diabetes, with its lead candidate Revita in pivotal development for post-GLP-1 weight maintenance.
11-06 12:00
11月3日,Fractyl Health(GUTS)收跌3.47%,报0.94美元,成交额22.95万美元,市值1250.32万美元。 行情数据 • 开盘价:...
11-03 08:54
Fractyl Health's market research highlights strong patient interest in Revita, a one-time endoscopic procedure for weight maintenance after GLP-1 therapy discontinuation. Approximately one million U.S. patients monthly stop GLP-1 medications, risking weight regain. One-third of surveyed GLP-1 users prefer a procedure over continued medication. Revita, designed to address post-GLP-1 weight maintenance, has shown promising results in clinical trial...
10-29 11:00
10月24日,Fractyl Health(GUTS)收跌4.42%,报1.08美元,成交额48.12万美元,市值1432.58万美元。 行情数据 • 开盘价...
10-24 07:55